Breo Ellipta (Asthma) – Forecast and Market Analysis to 2023: Order report by calling marketoptimizer.org at +1 888 391 5441 OR send an email on sales@marketoptimizer.org with Breo Ellipta (Asthma) – Forecast and Market Analysis to 2023 in subject line and your contact details. “Breo Ellipta(Asthma) – Forecast and Market Analysis to 2023″. The asthma market saw very slow growth over the past decade, as it has become saturated with relatively efficacious standard therapies, such as short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, and has also been facing increasing generic competition. However, the launch of seven novel targeted biologic agents and once-daily ICS and ICS/LABA therapies delivered by the next-generation inhalers will strongly drive the market growth over the next 10 years. The biologic agents will not only reshape the market growth, but will also mark the beginning of a new era of a personalized approach to asthma treatment. The realization that asthma is a very heterogeneous disease is highly reflected in the rich assortment of these targeted therapies in the late-stage pipeline. Breo Ellipta (or Relvar Ellipta in Europe) is an FDC of fluticasone furoate and vilanterol trifenatate for the maintenance treatment of asthma in patients who need both an ICS and a LABA. Breo is dosed via a new DPI device, Ellipta. Breo’s pharmacodynamics allow for once-daily administration, and it is going to be the first FDC that allows for once-daily administration for the maintenance treatment of asthma. This is due to its ICS component, fluticasone furoate, which is a synthetic trifluorinated corticosteroid with potent anti-inflammatory activity that can be dosed once a day, thus improving patient compliance and treatment outcomes. Fluticasone furoate is also being developed by GSK as a stand-alone ICS therapy. Complete report available at http://www.marketoptimizer.org/breo-elliptaasthma-forecast-andmarket-analysis-to-2023.html . Scope Overview of Asthma, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. Detailed information on Breo Ellipta including product description, safety and efficacy profiles as well as a SWOT analysis. Sales forecast for Breo Ellipta for the top eight countries from 2013 to 2023. Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia. Reasons to Buy Understand and capitalize by identifying products that are most likely to ensure a robust return Stay ahead of the competition by understanding the changing competitive landscape for Asthma Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential Make more informed business decisions from insightful and in-depth analysis of Breo Ellipta performance

Obtain sales forecast for Breo Ellipta from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and Australia) Inquire for discount @ http://www.marketoptimizer.org/contacts/discount?rname=10545 (Report price: Single user license- US$ 3495 ) Table of Contents 1 Table of Contents 1.1 List of Tables 1.2 List of Figures 2 Introduction 2.1 Catalyst 2.2 Related Reports 2.3 Upcoming Related Reports 3 Disease Overview 3.1 Etiology and Pathophysiology 3.1.1 Etiology 3.1.2 Pathophysiology 3.1.3 Prognosis 3.1.4 Quality of Life 3.2 Symptoms 4 Disease Management 4.1 Diagnosis and Treatment Overview 4.1.1 Diagnosis 4.1.2 Treatment Guidelines, Clinical Practice, and Leading Prescribed Drugs
Buy a Copy of the Report @ http://www.marketoptimizer.org/contacts/purchase?rname=10545 . Table of Contents 5 Competitive Assessment 5.1 Overview 5.2 Strategic Competitor Assessment
6 Breo Ellipta (fluticasone furoate/vilanterol trifenatate) 6.1 Overview 6.2 Efficacy 6.3 Safety 6.4 SWOT Analysis 6.5 Forecast 7 Appendix 7.1 Bibliography 7.2 Abbreviations 7.3 Methodology 7.4 Forecasting Methodology 7.4.1 Diagnosed Asthma Patients 7.4.2 Percent Drug-Treated Patients
Contact sales@marketoptimizer.org / Call +1 888 391 5441 for further information on “Breo Ellipta (Asthma) – Forecast and Market Analysis to 2023” report OR for any other market research and intelligence needs you may have for your business.